# **Program Highlights**

ICLE 2025 will showcase the most recent scientific advancements in lymphocyte engineering. It will also explore how these new findings can be used in the real world of medicine.

Take a look at the highlights below to learn more about what will be covered.

# REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.

# SUPERPOWERED LYMPHOCYTES

Learn more about engineering of lymphocytes for the coexpression of varied immune effectors in addition to the transgenic receptor.

#### NON-VIRAL CAR/TCR GENE TARGETING

Recent advancement in promoting integrations into lymphocyte genomes by means of nucleases or transposons.

# CAR/TCR MRNA THERAPIES

Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.

#### UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING

A deeper look at allogeneic therapies, including those applying genome editing technologies.

### UPDATED CLINICAL DATA

First look at post marketing real world data on the approved T cell therapies.

#### BEYOND ALPHA-BETA T CELLS

Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.

#### TARGETING NON-MALIGNANT DISEASES

Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.

#### IN VIVO AND BEDSIDE T CELL ENGINEERING

Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines and pre conditioning requirements.

EXPLORE THE FULL SCIENTIFIC PROGRAM